Sanofi's running Dengvaxia record: the November 2017 label restriction to seropositive recipients, the December 2018 FDA (Philippines) revocation of the certificate of product registration for post-marketing noncompliance — which Sanofi states the DOH confirmed was not safety-related — and the February 2019 DOJ reckless-imprudence allegations against officials and Sanofi executives, which Sanofi denies and says remain in litigation.
not related to the safety of the vaccine, as confirmed by the Department of Health
Sanofi's running Dengvaxia record: the November 2017 label restriction to seropositive recipients, the December 2018 FDA (Philippines) revocation of the certificate of product registration for post-marketing noncompliance — which Sanofi states the DOH confirmed was not safety-related — and the February 2019 DOJ reckless-imprudence allegations against officials and Sanofi executives, which Sanofi denies and says remain in litigation. current to October 2026. Company account of proceedings involving its own product; the DOH suspension and program scale are documented independently in MME-44.